From GlobeNewswire: 2024-09-18 08:30:00

BioCardia, Inc. has regained compliance with Nasdaq Capital Market listing requirements, as confirmed on September 17, 2024. This follows the company’s efforts to improve its balance sheet, including raising new capital for therapeutic development. They have achieved milestones such as FDA approvals, successful trials, and market clearances for products like the CardiAMP® Cell Therapy and Morph® DNA™. BioCardia’s President and CEO, Peter Altman, highlights upcoming goals in trials and product development to treat cardiovascular and pulmonary diseases. The company’s focus on cellular and cell-derived therapeutics for these diseases remains steadfast. BioCardia is a global leader based in Sunnyvale, California.



Read more at GlobeNewswire: BioCardia Regains Full Compliance with Nasdaq Listing